SEC EDGAR - Form 8-K Filings

Rocket Pharmaceuticals Files 8-K on Entry into Material Definitive Agreement

Rocket Pharmaceuticals, Inc. (CIK: 0001281895), a Delaware corporation headquartered at 350 Fifth Avenue, Suite 7530, New York, NY 10118, filed a Form 8-K current report with the SEC on April 28, 2026 (Period of Report: April 26, 2026). The filing discloses entry into a Material Definitive Agreement under Item 1.01, a Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. The company operates under SIC 2834 (Pharmaceutical Preparations) and trades under File No. 001-36829.

Wave Life Sciences 8-K Reports Q1 2026 Results

Wave Life Sciences Ltd. filed a Form 8-K current report with the SEC on April 28, 2026, disclosing results of operations and financial condition under Item 2.02, along with a Regulation FD disclosure under Item 7.01 and financial statements and exhibits under Item 9.01. The filing includes two exhibits (EX-99.1 and EX-99.2) and was accepted at 07:34:43 Eastern Time. Wave Life Sciences is a pharmaceutical preparations company (SIC 2834) incorporated under the laws of a foreign jurisdiction, with its primary business address in Cambridge, Massachusetts and operational presence in Singapore.

Kiniksa Pharmaceuticals Reports Q1 2026 Financial Results

Kiniksa Pharmaceuticals International, plc filed a Form 8-K current report with the SEC on April 28, 2026, reporting financial results for the first quarter of 2026. The filing discloses Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), with supporting exhibit EX-99.1 attached. The company, headquartered at 105 Piccadilly, Second Floor, London, is a biopharmaceutical firm operating in the pharmaceutical preparations industry (SIC 2834) with EIN 981795578 and CIK 0001730430.